Sort
82,697 grants matching “vaccine development”
NIAID Preclinical Development Support: Essential Core Activities
$712,914Timothy R Fouts · Advanced Bioscience Laboratories, Inc. · N01 · FY2024 · AI
Multivalent Tick-Microbe targeted Lyme disease vaccines
$712,910Utpal Pal · Univ Of Maryland, College Park · R01 · FY2021 · AI
Antigen presentation by epithelial stem cells to promote life long immunity
$712,909Marie-Claire Elisabeth Gauduin · Texas Biomedical Research Institute · R01 · FY2013 · AI
Bronx-Lebanon Hospital Center Pediatric ACTU
$712,836Bronx-Lebanon Hosp Ctr (Bronx, Ny) · U01 · FY2003 · AI
Assessing the determinants of durable protective immunity in SARS-CoV-2 infected human subjects
$712,821Stefan H.i. Kappe · Seattle Children'S Hospital · U01 · FY2021 · AI
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment
$712,803Christopher D Vanderwal · University Of California-Irvine · R01 · FY2020 · AI
The Role of Group 3 Innate Lymphoid cells (ILC3) in Tuberculosis
$712,802Shabaana A. Khader · Washington University · R01 · FY2017 · AI
Studies of Receptor Interactions and Effects of Alarmins
$712,775Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Joint Initiative in Vaccine Economics (JIVE) Project
$712,764Tracy A Lieu · Harvard Pilgrim Health Care, Inc. · U01 · FY2006 · IP
B-cell repertoire analysis in influenza vaccination and infection
$712,744Hua-Xin Liao · Boston Children'S Hospital · P01 · FY2013 · AI
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
$712,726Mayumi Nakagawa · Univ Of Arkansas For Med Scis · R01 · FY2022 · CA
Development of a Replicon RNA-based Vaccine against Dengue and Zika
$712,699Sujan Shresta · La Jolla Institute For Immunology · R01 · FY2022 · AI
Development of a Replicon RNA-based Vaccine against Dengue and Zika
$712,699Sujan Shresta · La Jolla Institute For Immunology · R01 · FY2021 · AI
Targeting 5' leader-encoded defective ribosomal products for HIV T cell vaccines
$712,679George M Shaw · University Of Pennsylvania · R01 · FY2018 · AI
Bronx-Lebanon Hospital Clinical Trials Unit
$712,621Murli U Purswani · Bronxcare Health System · U01 · FY2010 · AI
Carbohydrate Antigen-bearing Nanoparticles for Antitumor Therapy
$712,618Joseph John Barchi · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Discovery of long-acting, chemoprotective antimalarial compounds
$712,608Elizabeth A Winzeler · University Of California, San Diego · R01 · FY2021 · AI
A Novel HIV-1 Vaccine Targeting the 12 protease Cleavage Sites
$712,570Ma Luo · University Of Manitoba · R01 · FY2017 · AI
Systems Biology
$712,541Rafick-Pierre Sekaly · Beth Israel Deaconess Medical Center · U19 · FY2011 · AI
Adolescent health behaviors in the time of COVID-19
$712,539Michele Ybarra · Center For Innovative Public Health Research · R01 · FY2022 · HD
SARS-CoV-2 Studies
$712,523Douglas Bell · National Institute Of Environmental Health Sciences · ZIA · FY2021 · ES
Acquisition of HCMV from breast milk-correlates of protection
$712,448Suresh B Boppana · University Of Alabama At Birmingham · R01 · FY2016 · AI
The Role of Nasal Mucosal Immunity and Microbiome on the Frequent Exacerbation Phenotype of COPD
$712,444Michael Bradley Drummond · Univ Of North Carolina Chapel Hill · R01 · FY2024 · HL
Immunogen Design for SARS-CoV-2
$712,375Peter D Kwong · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Identification, structures and ontogenies of SARS-CoV-2 antibodies
$712,375Tongqing Zhou · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI